Avalyn Pharma Inc. Common Stock
AVLN | NASDAQ
$25.63
-$0.08 (-0.31%)
At close: Oct 30, 2026, 4:00 PM ET
$23.20
-$2.43 (-9.48%)
Pre-market:
Nov 2, 2026, 6:23 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 |
|---|---|
Revenue | n/a |
Cost of Revenue | n/a |
Gross Profit | n/a |
Operating Income | -91.29M |
Interest Income | 6.18M |
Pretax Income | -85.2M |
Net Income | -85.2M |
Selling & General & Admin | 14.68M |
Research & Development | 76.61M |
Other Expenses | n/a |
Operating Expenses | 91.29M |
Interest Expense | n/a |
Selling & Marketing Expenses | n/a |
Cost & Expenses | 91.29M |
Income Tax Expense | n/a |
Shares Outstanding (Basic) | 41.81M |
Shares Outstanding (Diluted) | 41.81M |
EPS (Basic) | -2.04 |
EPS (Diluted) | -2.04 |
EBITDA | -91.25M |
EBIT | -91.29M |
Depreciation & Amortization | 42K |
Add to Watchlist
Select watchlists to add or remove AVLN